Optimized Dosing Delivers Enhanced Motor Benefits: FDA Approves High-Dose Spinraza Regimen for Spinal Muscular Atrophy

A decade of accumulated clinical experience with nusinersen has culminated in a significant regulatory advancement. According to Pharma Times Online, Biogen's newly approved high-dose Spinraza regimen represents a thoughtful evolution…

Continue Reading Optimized Dosing Delivers Enhanced Motor Benefits: FDA Approves High-Dose Spinraza Regimen for Spinal Muscular Atrophy
England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen
source: pixabay.com

England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen

According to a publication from Express Digest, Britain's National Health Service (NHS) has finally reached an agreement with American biotechnology company Biogen Inc. over the price of Spinraza - a…

Continue Reading England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen
Patients with Spinal Muscular Atrophy Celebrate First FDA-Approved Treatment
https://pixabay.com/en/balloons-party-colors-rubber-fly-1786430/

Patients with Spinal Muscular Atrophy Celebrate First FDA-Approved Treatment

Did you know that the #1 genetic cause of death for infants is spinal muscular atrophy (SMA)? It quickly robs the infant of physical strength, rendering the child unable to…

Continue Reading Patients with Spinal Muscular Atrophy Celebrate First FDA-Approved Treatment